Physicians reported that clinical treatment guidelines (88%), goals of therapy (68%) and recommendations from opinion leaders (52%) were the factors most considered when making treatment decisions regarding patients with HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.